New Technologies Against Allergies are on the Wave
Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1…
Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1…
The relevance of biotechnology is certainly not restricted to the human domain, and rightly so,…
Ascendis Pharma, a biotechnology company that applies its innovative TransCon technology to address significant unmet medical…
What could you buy with €1,1M euros? A house? Or a single prescription for a new…
Oxford BioTherapeutics and Menarini Group have initiated the first-in-human clinical study of OBT357, a novel enhanced…
Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of…
Theravalues Corporation, Tokyo based company, will launch Theracurmin® Super for the European market at Hi Europe 2014,…
Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment…
The US pharmaceutical company Allergan, known for their Botox, agreed an Actavis bid of 53…
The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue…
Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents…
France has great Synthetic Biology Biotech companies. Paris-based Global Bioenergies carried out the first isobutene…